phillyrin has been researched along with Cardiomegaly in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, D; Chen, X; Li, X; Liu, Q; Luo, Q; Tang, K; Yang, S; Zhong, B | 1 |
1 other study(ies) available for phillyrin and Cardiomegaly
| Article | Year |
|---|---|
Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38/ERK1/2 MAPK and AKT/NF-kappaB pathways.
Topics: Animals; Cardiomegaly; Glucosides; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Norepinephrine; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Rats | 2022 |